echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > New company announces IPO plan New ideas to challenge the success of Alzheimer's disease?

    New company announces IPO plan New ideas to challenge the success of Alzheimer's disease?

    • Last Update: 2020-09-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Seattle-based biopharmaceutical company Athira Pharma announced its IPO today with an estimated funding target of $100m.
    in June, Athira had just completed an $85 million round of B financing.
    Athira focuses on drug development for neurodegenerative diseases and is advancing the NDX-1017 program for the treatment of Alzheimer's disease (AD).
    AD is a serious aggressive neurodegenerative disease with complex causes, and genetic and environmental factors can cause the disease alone or as a combination of causes.
    specifically, disease-related factors include oxidative stress, inflammation, loss of the neurotransmitter acetylcholine, gliosis, and abnormal protein pathology of Tau and beta amyloid proteins.
    these changes can lead to a decrease in synapses in the brain, and the number of synapses is highly correlated with memory and cognitive abilities, and synapse reduction eventually leads to AD.
    the past decade, the development of AD drugs has been based on a strategy to reduce the deposition of beta amyloid protein.
    in Alzheimer's patients, beta amyloid oligomers bind to the subjects on synapses, interfering with synapses and causing synapses to become abnormal.
    but this strategy has failed repeatedly over the past decade.
    Athira has adopted a different strategy, trying to permanently change the progression of the disease by activating key neurotrophic factors in the brain, restoring lost neural connections, or creating new neural connections.
    Athira's main drug candidate, NDX-1017, targets hepatocellular growth factor (HGF) and its subject MET, promoting the proliferation and survival of neurons and addressing the underlying mechanisms of neurodegenerative lesions, thereby improving connections between nerve cells in the brain.
    NDX-1017 also showed positive efficacy characteristics in Athira's Phase I clinical trials.
    despite the failure of several large multinational pharmaceutical companies in late-stage clinical trials in the treatment of Alzheimer's disease, Capital continues to focus on the field of neurodegenerative disease drugs.
    year, several companies have completed different rounds of financing, and Annovis Bio has completed IPOs.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.